Date Log
Copyright (c) 2020 International Journal of Allied Medical Sciences and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Successful management of esthesioneuroblastoma with chemoradiotherapy: Report of 3 cases with review of literature
Corresponding Author(s) : Dr Gunjesh Kumar Singh
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 5 No. 3 (2017): 2017 Volume 5- Issue -3
Abstract
ABSTRACTEsthesioneuroblastoma (ENB) is a rare malignant tumour, which arises from the basal progenitor cells of the olfactory epithelium. Histopathological diagnosis is often difficult and is based on antigen detection by immunohistochemistry. The optimal treatment is still debated. Surgery followed by adjuvant radiotherapy is the recommended treatment for localised tumour, however, majority of the patients usually present in an advanced stage. We present a case series of three patients who were treated at our Institute with chemotherapy and radiotherapy between the years 2011 and 2016. Although no standard treatment protocol has been established, but combined modality therapy is the cornerstone of treatment for ENB. Chemotherapy can be added in advanced and metastatic disease. None of the patients received definitive surgical treatment. All three patients were treated by radiotherapy and chemotherapy, with endoscopic removal of the tumour done in one case. The patients were disease free during the follow-up period of 48 months, 14 months and 3 months.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
-
Berger L, Luc R, Richard D. Olfactory esthesioneuroblastoma. Bull Assoc Fr Etude Cancer. 13, 1924, 410–421. (In French).
[2]. Song CM, Won TB, Lee CH, Kim DY, Rhee CS. Treatment modalities and outcomes of olfactory neuroblastoma. Laryngoscope. 122, 2012, 2389–2395.
[3]. Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 133, 2007, 276–280. [4]. Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 123, 1997, 34–40.
[5]. Kleihues P and Cavenee WK. WHO Classification of Tumours of Pathology and Genetics Tumours of the Nervous System. Lyon, France: IARC Press. 2000, 150–152.
[6]. Weiss SW and Goldblum JR Enzinger. Primitive neuroectodermal tumors and related lesions. Enzinger and Weiss's Soft Tissue Tumors. (Philadelphia, PA). Mosby Elsevier, 4, 2001, 1308–1311. [7]. Lin JH, Tsai DH, Chiang YH. A primary sellar esthesioneuroblastomas with unusual presentations: a case report and reviews of literatures. Pituitary. 2009, 12:70-5. [8]. Kadish S, Goodman M, Wang C. Olfatory neuroblastoma: A clinical analysis of 17 cases. Cancer. 37, 1976, 1571–6. [9]. Morita A, Ebersolod M, Olsen K, Foote R, Lewis J, Quasqst L. Esthesioneuroblastoma: Prognosis and management. Neurosurgery. 32, 1993, 706–15. [10]. Tseng J, Michel MA, Loehrl TA. Peripheral cysts: a distinguishing feature of esthesioneuroblastoma with intracranial extension. Ear Nose Throat J 88, 2009, E14. [11]. Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 28, 2006, 305-312 [12]. Casiano RR, Numa WA and Falquez AM. Endoscopic resection of esthesioneuroblastoma. Am. J. Rhinol. 15, 2001, 271-279. [13]. Dulguerov P, Allal AS and Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2, 2001, 683–90.
[14]. Tajudeen BA, Arshi A, Suh JD, St John M, Wang MB. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg. 140, 2014, 1124-9. [15]. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 102, 1992, 843–849
References
[2]. Song CM, Won TB, Lee CH, Kim DY, Rhee CS. Treatment modalities and outcomes of olfactory neuroblastoma. Laryngoscope. 122, 2012, 2389–2395.
[3]. Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 133, 2007, 276–280. [4]. Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 123, 1997, 34–40.
[5]. Kleihues P and Cavenee WK. WHO Classification of Tumours of Pathology and Genetics Tumours of the Nervous System. Lyon, France: IARC Press. 2000, 150–152.
[6]. Weiss SW and Goldblum JR Enzinger. Primitive neuroectodermal tumors and related lesions. Enzinger and Weiss's Soft Tissue Tumors. (Philadelphia, PA). Mosby Elsevier, 4, 2001, 1308–1311. [7]. Lin JH, Tsai DH, Chiang YH. A primary sellar esthesioneuroblastomas with unusual presentations: a case report and reviews of literatures. Pituitary. 2009, 12:70-5. [8]. Kadish S, Goodman M, Wang C. Olfatory neuroblastoma: A clinical analysis of 17 cases. Cancer. 37, 1976, 1571–6. [9]. Morita A, Ebersolod M, Olsen K, Foote R, Lewis J, Quasqst L. Esthesioneuroblastoma: Prognosis and management. Neurosurgery. 32, 1993, 706–15. [10]. Tseng J, Michel MA, Loehrl TA. Peripheral cysts: a distinguishing feature of esthesioneuroblastoma with intracranial extension. Ear Nose Throat J 88, 2009, E14. [11]. Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 28, 2006, 305-312 [12]. Casiano RR, Numa WA and Falquez AM. Endoscopic resection of esthesioneuroblastoma. Am. J. Rhinol. 15, 2001, 271-279. [13]. Dulguerov P, Allal AS and Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2, 2001, 683–90.
[14]. Tajudeen BA, Arshi A, Suh JD, St John M, Wang MB. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg. 140, 2014, 1124-9. [15]. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 102, 1992, 843–849